CDK-002 is under clinical development by Codiak BioSciences and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CDK-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CDK-002 overview

CDK-002 is under development for the treatment of solid tumors including triple-negative breast cancer and head and neck squamous cell carcinoma, HCC, cutaneous squamous cell carcinoma, anaplastic thyroid cancer, glioblastoma multiforme (GBM), cervical cancer, sarcomas, muscle invasive bladder cancer (MIBC) and leptomeningeal disease (LMD). The therapeutic candidates comprise of genetically altered exosomes overexpressing PTGFRN and loaded with a cyclic dinucleotide (CDN) small molecule STING agonist which gets delivered to antigen presenting cells (APC). They are developed based on engEx platform. It is administered through intratumor and intrathecal route. It was also under development for the treatment of lung cancer and infectious diseases.

Codiak BioSciences overview

Codiak BioSciences is an exosome therapeutics company. The company focuses on the development of proprietary pipeline of targeted medicines for diseases with unmet medical needs. Its engEx platform capitalizes on exosomes, which are nanometer-sized membrane sacs that delivers proteins, lipids, nucleic acids, and small molecules to various cell types. Codiak BioSciences latest pipeline products includes exoSTING, exoIL-12, exoASO-STAT6, oncogene targets, exoASO-NLRP3, gene targets, exoVACC and exoASO-NRAS. The company also has rights to a novel investigational drug candidate for the treatment of pancreatic cancer, from The University of Texas, MD Anderson Cancer Center. Codiak BioSciences is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of CDK-002’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.